A randomized, controlled trial of oral propranolol in infantile hemangioma

New England Journal of Medicine

Volumn 372, Issue 8, 2014, Pages 735-746

  Leaute Labreze C ^a   Hoeger, P ^l   Mazereeuw Hautier, J ^b   Guibaud, L ^c   Baselga, E ^p   Posiunas, G ^v   Phillips, R J ^w   Caceres, H ^ad   Lopez Gutierrez, J C ^q   Ballona, R ^ac   Friedlander, S F ^ae   Powell, J ^af   Perek, D ^ag   Metz, B ^aj   Barbarot, S ^d   Maruani, A ^e   Szalai, Z Z ^ak   Krol, A ^al   Boccara, O ^f   Foelster Holst, R ^m   Febrer Bosch, M I ^s   Su, J ^x   Buckova, H ^ab   Torrelo, A ^r   Cambazard, F ^h   Grantzow, R ⁿ   Wargon, O ^z,aa   Wyrzykowski, D ^ah   Roessler, J ^o   Bernabeu Wittel, J ^t   Valencia, A M ^u   Przewratil, P ^ai   Glick, S ^am   Pope, E ^an   Birchall, N ^ao   Benjamin, L ^ap   Mancini, A J ^aq   Vabres, P ⁱ   Souteyrand, P ^j   Frieden, I J ^ar   Berul, C I ^as   Mehta, C R ^at   Prey, S ^a   Boralevi, F ^a   Morgan, C C ^g   Heritier, S ^y   Delarue, A ^k   Voisard, J J ^k   more..

^a HÔPITAL PELLEGRIN   (France)

^b HÔPITAL DES ENFANTS   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ DE TOURS   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g Cardinal Systems   (France)

^h HÔPITAL NORD   (France)

ⁱ HÔPITAL DU BOCAGE   (France)

^j HÔTEL DIEU   (France)

^k Centre d'Immunologie Pierre Fabre   (France)

^l Kinderkrankenhaus Wilhelmstift   (Germany)

^m UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁿ UNIVERSITY OF MUNICH   (Germany)

^o UNIVERSITY OF FREIBURG   (Germany)

^p HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^q HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^r HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^s HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^t HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^u HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^v VILNIUS UNIVERSITY   (Lithuania)

^w ROYAL CHILDREN'S HOSPITAL   (Australia)

^x BOX HILL HOSPITAL   (Australia)

^y Centre of Cardiovascular Research Education in Therapeutics School of Public Health and Preventive Medicine   (Australia)

^z MONASH UNIVERSITY   (Australia)

^aa SYDNEY CHILDREN'S HOSPITAL   (Australia)

^ab UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^ac Clinica Internacional   (Peru)

^ad INSTITUTO NACIONAL DE SALUD DEL NIÑO   (Peru)

^ae RADY CHILDREN'S HOSPITAL   (United States)

^af UNIVERSITY OF MONTREAL   (Canada)

^ag CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^ah MEDICAL UNIVERSITY OF GDANSK   (Poland)

^ai MEDICAL UNIVERSITY OF LODZ   (Poland)

^aj UNIVERSITY OF CALIFORNIA   (United States)

^ak Pal Heim Children's Hospital   (Hungary)

^al OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^am SUNY DOWNSTATE MEDICAL CENTER   (United States)

^an HOSPITAL FOR SICK CHILDREN   (Canada)

^ao Auckland Dermatology   (New Zealand)

^ap STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^aq Ann and Robert H Lurie Children's Hospital   (United States)

^ar UNIVERSITY OF CALIFORNIA   (United States)

^as CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^at Cytel Corporation   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROPRANOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; BRADYCARDIA; BRONCHOSPASM; CAPILLARY HEMANGIOMA; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SLEEP DISORDER; TREATMENT DURATION; CHEMICALLY INDUCED; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; HEMANGIOMA; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMANGIOMA; HUMANS; HYPOTENSION; INFANT; MALE; PROPRANOLOL; TREATMENT OUTCOME;

EID: 84922978972     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1404710     Document Type: Article

References (37)

1. Frieden IJ, Eichenfield LF, Esterly NB, Geronemus R, Mallory SB. Guidelines of care for hemangiomas of infancy: American Academy of Dermatology Guidelines/Outcomes Committee. J Am Acad Dermatol 1997;37:631-7.
2. Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol 2008;25:168-73.
3. Hoornweg MJ, Smeulders MJ, van der Horst CM. Prevalence and characteristics of haemangiomas in young children. Ned Tijdschr Geneeskd 2005;149:2455-8. (In Dutch.)
4. Munden A, Butschek R, Tom WL, et al. Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies. Br J Dermatol 2014;170:907-13.
5. Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics 2008;122:360-7.
6. Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics 2013;131: 128-40.
7. Hemangioma Investigator Group. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 2007;150:291-4.
8. Bauland CG, Lüning TH, Smit JM, Zeebregts CJ, Spauwen PH. Untreated hemangiomas: growth pattern and residual lesions. Plast Reconstr Surg 2011;127:1643-8.
9. Frieden IJ, Haggstrom AN, Drolet BA, et al. Infantile hemangiomas: current knowledge, future directions - proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA. Pediatr Dermatol 2005; 22:383-406.
10. Zarem HA, Edgerton MT. Induced resolution of cavernous hemangiomas following prednisolone therapy. Plast Reconstr Surg 1967;39:76-83.
11. Enjolras O, Riche MC, Merland JJ, Escande JP. Management of alarming hemangiomas in infancy: a review of 25 cases. Pediatrics 1990;85:491-8.
12. Barrio VR, Drolet BA. Treatment of hemangiomas of infancy. Dermatol Ther 2005;18:151-9.
13. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992;326:1456-63. [Errata, N Engl J Med 1994;330:300, 1995;333:595-6.]
14. Enjolras O, Brevière GM, Roger G, et al. Vincristine treatment for function- and life-threatening infantile hemangioma. Arch Pediatr 2004;11:99-107. (In French.)
15. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358:2649-51.
16. Sans V, de la Roque ED, Berge J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 2009; 124:e423-31.
17. Izadpanah A, Izadpanah A, Kanevsky J, Belzile E, Schwarz K. Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis. Plast Reconstr Surg 2013; 131:601-13.
18. Price CJ, Lattouf C, Baum B, et al. Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis. Arch Dermatol 2011;147: 1371-6.
19. Bertrand J, McCuaig C, Dubois J, Hatami A, Ondrejchak S, Powell J. Propranolol versus prednisone in the treatment of infantile hemangiomas: a retrospective comparative study. Pediatr Dermatol 2011;28: 649-54.
20. Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 2011;128:e259-66.
21. Léauté-Labrèze C, Dumas de la Roque E, Nacka F, et al. Double-blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants <4 months of age. Br J Dermatol 2013;169:181-3.
22. Mabeta P, Pepper MS. Hemangiomas - current therapeutic strategies. Int J Dev Biol 2011;55:431-7.
23. Posch M, Koenig F, Branson M, Brannath W, Dunger-Baldauf C, Bauer P. Testing and estimation in flexible group sequential designs with adaptive treatment selection. Stat Med 2005;24:3697-714.
24. Heritier S, Lô SN, Morgan CC. An adaptive confirmatory trial with interim treatment selection: practical experiences and unbalanced randomization. Stat Med 2011;30:1541-54.
25. Bowers RE, Graham EA, Tomlinson KM. The natural history of the strawberry nevus. Arch Dermatol 1960;82:667-80.
26. Lister WA. The natural history of strawberry naevi. Lancet 1938;1:1429-34.
27. Simes RJ. An improved Bonferroni procedure for multiple tests of significance. Biometrika 1986;73:751-4.
28. Jennison C, Turnbull BW. Adaptive seamless designs: selection and prospective testing of hypotheses. J Biopharm Stat 2007;17:1135-61.
29. Ahogo CK, Ezzedine K, Prey S, et al. Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol. Br J Dermatol 2013;169:1252-6.
30. Hermans DJ, van Beynum IM, Schultze Kool LJ, van de Kerkhof PC, Wijnen MH, van der Vleuten CJ. Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. J Am Acad Dermatol 2011;64:833-8.
31. Saint-Jean M, Léauté-Labrèze C, Mazereeuw-Hautier J, et al. Propranolol for treatment of ulcerated infantile hemangiomas. J Am Acad Dermatol 2011;64: 827-32.
32. Haider KM, Plager DA, Neely DE, Eikenberry J, Haggstrom A. Outpatient treatment of periocular infantile hemangiomas with oral propranolol. J AAPOS 2010;14:251-6.
33. Snir M, Reich U, Siegel R, et al. Refractive and structural changes in infantile periocular capillary haemangioma treated with propranolol. Eye (Lond) 2011; 25:1627-34.
34. Fuchsmann C, Quintal MC, Giguere C, et al. Propranolol as first-line treatment of head and neck hemangiomas. Arch Otolaryngol Head Neck Surg 2011;137: 471-8.
35. Mazereeuw-Hautier J, Hoeger PH, Benlahrech S, et al. Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. J Pediatr 2010;157:340-2.
36. Metry D, Frieden IJ, Hess C, et al. Propranolol use in PHACE syndrome with cervical and intracranial arterial anomalies: collective experience in 32 infants. Pediatr Dermatol 2013;30:71-89.
37. Phillips RJ, Penington AJ, Bekhor PS, Crock CM. Use of propranolol for treatment of infantile haemangiomas in an outpatient setting. J Paediatr Child Health 2012;48:902-6.